PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
PHAXIAM Therapeutics (Nasdaq & Euronext: FR0011471135), today announces the enrolment of the 1st patient in the phase 1 clinical study in endocarditis infection caused by Staphylococcus aureus (S. aureus). Endocarditis is an infection of the endocardium (inner lining of the…
WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates
WuXi Biologics (“WuXi Bio”) (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that its Research Service Unit (R in CRDMO) has signed a research service agreement with BioNTech SE (Nasdaq: BNTX, “BioNTech”), a next generation…
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study
Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir’s licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has dosed the first patient with TNG348, a novel…
Oncoclínicas opens first Cancer Center in Brazil as an International Collaborative Member of Dana-Farber Cancer Institute
Oncoclínicas&Co, the largest group dedicated to cancer in Latin America, and Dana-Farber Cancer Institute, a Harvard Medical School affiliated teaching hospital and one of the world’s leading cancer treatment and oncology research institutions, announce the expansion of their collaboration with the opening of…